scholarly journals Fragmentation of Care for Young Adults with Sickle Cell Disease in California

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4667-4667
Author(s):  
Ashley Shatola ◽  
Ann M Brunson ◽  
Theresa H.M. Keegan ◽  
Ted Wun ◽  
Anjlee Mahajan

Background: Sickle Cell Disease (SCD) predominantly affects people of African ancestry, causing significant morbidity and mortality. In high-income countries children, who are more likely to receive comprehensive care than adults, have better health care outcomes. Young adults (YA) are in a period of transition from pediatric to adult models of care and the effect of receiving care at multiple medical facilities (fragmentation) during this time on outcomes has not been well-described. In this study we sought to examine fragmentation of care for YA SCD patients and the association of fragmentation on mortality. Methods: Using a previously published definition, longitudinal records from the California Patient Discharge, Emergency Department, and Ambulatory Surgery datasets were used to identify SCD patients from 1991-2016. SCD patients were placed into three different age cohorts: children (10-17), YA (18-25) and adults (26-33). Each patient required the full 7 year follow up time in each age category; patients could be in multiple age cohorts. Patients with no inpatient admissions were excluded. The number of inpatient admissions during each age group period was used as a measure of disease severity (<10, 10-19, 20-29, ≥30). SCD specialty care centers (SCD SC) were determined using all SCD inpatient admissions; facilities in the top 5% based on number of unique SCD patients seen were considered SCD SC. Patients were classified as always, sometimes and never seen at SCD SC facilities in each age group. We classified care fragmentation by the number of facilities an individual received inpatient care (1, 2, 3-4 or ≥5 unique facilities) during their time in each age group. Descriptive statistics were used to describe patients' characteristics by age group. Multivariable Poisson regression was used to identify risk factors associated with fragmented care. Multivariable Cox regression was used to determine the impact of fragmented care, disease severity and care at SCD SC on all-cause mortality, conditional on surviving to 26 years of age for the YA group. Results We identified a cohort of 6,977 unique SCD patients: 1,019 children, 1,122 YAs and 1,015 adults. The YA cohort consisted of predominately African Americans (91.3%) with 43.9% male and 56.1% female. Forty-two % YAs had Medi-Cal followed by 26.7% with private insurance as first reported health insurance. Forty-four % (494) had <10, 20.1% (226) had 10-19, 11.1% (125) had 20-29 and 24.7% (277) had ≥30 inpatient admissions while in the YA age period. Twenty-two % (248) YAs were seen at 1, 25.8% (290) were seen at 2, 30.2% (339) were seen at 3-4, and 21.8% (245) were seen at > 5 inpatient facilities. YAs and older adults were seen at a similar number of facilities while children were seen at less (Figure 1). In multivariable regression models among YAs, those with private insurance (vs. Medi-Cal) were at lower risk of fragmentation (Incident Rate Ratio (IRR)=0.85, CI 0.78-0.93, p=0.0002), while those without insurance were at a higher risk (IRR 1.45, CI 1.22-1.72, p<0.0001). Patients with more admissions (vs. <10) were at higher risk of fragmentation (IRR for 10-19 =1.42, CI 1.29-1.57; IRR for 20-29 1.49, CI 1.33-1.67, IRR for >30 admissions 2.13, CI 1.98-2.43 p<0.0001). Patients who were sometimes admitted to an SCD SC (IRR=2.19, CI 1.98-2.43, p<0.0001) or never (IRR=1.15, CI 1.15-1.46, p<0.0001) were at increased risk of fragmented care compared to those who were always admitted to an SCD SC. In the multivariable mortality model, YAs with increasing number of admissions, regardless of location, were at increased risk of death (10-19 HR 2.36, CI 1.13-4.91 p=0.022; 20-29 HR 4.25, CI 2.03-8.92, p=0.0001; > 30 admissions HR 7.79, CI 4.09-14.83, p<0.0001). Fragmentation of care and always or sometimes being admitted to an SCD SC were not associated with mortality. Conclusion Most young adult SCD patients (78%) received inpatient care at >1 facility. Of all age groups, children were most likely to be seen at only 1 facility, suggesting that fragmentation of care begins in early adulthood. Young adults without insurance, patients with more frequent admissions and those who did not always receive care at an SCD SC were at higher risk for fragmented care. Young adults with more frequent admissions were also at an increased risk of mortality. The effect of specialty centers and more consistent location of care on health-related outcomes for patients with SCD requires further study. Disclosures Wun: Janssen: Other: Steering committee; Pfizer: Other: Steering committee.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 432-432 ◽  
Author(s):  
John J. Strouse ◽  
Carlton Haywood ◽  
Sophie Lanzkron

Abstract Most studies of survival in sickle cell disease (SCD) include only patients followed at referral centers. We used the public set of the California Patient Discharge Databases (1998–2005) to compare in-hospital mortality and charges by patient characteristics. We included discharges with any diagnostic code for SCD (282.41–2, 282.60–69). We used the Charlson index (adapted for administrative data) to adjust for comorbid conditions. Hospital charges were adjusted to 1998 levels. Statistical methods included ANOVA, Wilcoxon rank-sum, and multivariate linear and logistic regression. We identified 57,887 admissions for SCD and 376 in-hospital deaths (0.65%) from 1998–2005. The mean age of death was 40 years (95% CI 38–42) for sickle cell anemia (HbSS) and 48.3 years (95% CI 44.1–52.5, p<.0005) for all other SCD. Median length of stay was 4 days (IQR 2–7 days) and charges were $10,027 (IQR 5547–18,302) for HbSS and 4 days (IQR 2–6 days) and $8045 (IQR 4375–16,253) for all other SCD (p<.0001). Women with SCD were older at the time of death (43.6 years) than men (41.4 years, p=.29) and age of death increased from 40.6 years in 1998–2000 to 44.2 in 2004–2005 (p=.17) but these differences were not significant. Mortality was increased with a Charlson Index of 1 or 2, older age, private insurance, a diagnosis of HbSS, and transfusion during the admission (Table 1). Women had a lower odds of death than men (OR 0.7, p<.05). Average annual charges for hospitalization in patients with SCD, adjusted to 1998 values, were $117,000,000 and decreased $1,960,000/year (−4.1%, p<.0001) for children and increased $1,150,000/year (1.4% p<0.05) for adults. Adjusted charges for all children were stable and increased 1.5% per year for adults. Charges per admission were $3167 higher for adults than children, $5608 higher per comorbid diagnosis, $6506 higher in transfused patients, and $3595 higher with a diagnosis of crisis (p<.0001 for all). Compared to MediCal, charges were $1186 higher for Medicare (p<.05), $2651 lower for other government insurance (p<.0001), and $3521 lower for self-pay (p<.05). Government (77%) and private insurance (21%) paid for most admissions. We identified a greatly increased risk of in-hospital morality with comorbid diagnoses and older age and moderately increased risk with private insurance, HbSS genotype, and transfusion during the admission. The increased risk with private insurance was surprising, as higher socioeconomic status is often associated with better health outcomes. This may reflect more stringent requirements for admission or financial barriers to outpatient and preventive services for SCD. Total charges decreased dramatically in children, possibly reflecting increased use of hydroxyurea for frequent pain and chronic transfusions for primary stroke prevention. Table 1: Odds Ratio for In-Hospital Death Based on Multivariate Logistic Regression Variable Odds Ratio (95% CI) P-Value NS indicates not significant Charlson Index=1 3.3 (2.4–4.6) <.0001 Charlson Index=2 12.9 (9.3–18) <.0001 Age (per year) 1.04 (1.03–1.05) <.0001 Private Insurance vs. MediCal 1.6 (1.2–2.2) <.0005 Medicare vs. MediCal 0.9 (0.7–1.3) NS Other SCD vs. HbSS 0.7 (0.5–0.9) <.0005 Transfusion 1.6 (1.2–2.0) <.0001


2017 ◽  
Vol 42 (9) ◽  
pp. 1016-1027 ◽  
Author(s):  
Jerlym S. Porter ◽  
Kimberly M. Wesley ◽  
Mimi S. Zhao ◽  
Rebecca J. Rupff ◽  
Jane S. Hankins

PEDIATRICS ◽  
1974 ◽  
Vol 54 (4) ◽  
pp. 438-441
Author(s):  
Gerald Erenberg ◽  
Steven S. Rinsler ◽  
Bernard G. Fish

Four cases of lead neuropathy in children with hemoglobin S-S or S-C disease are reported. Neuropathy is a rare manifestation of lead poisoning in children, and only ten other cases have been well documented in the pediatric literature. The last previous case report of lead neuropathy was also in a child with hemoglobin S-S disease. The neuropathy seen in the children with sickle cell disease was clinically similar to that seen in the previously reported cases in nonsicklers, but differed in both groups from that usually seen in adult cases. It is, therefore, postulated that children with sickle cell disease have an increased risk of developing neuropathy with exposure to lead. The exact mechanism for this association remains unknown, but in children with sickle cell disease presenting with symptoms or signs of peripheral weakness, the possibility of lead poisoning must be considered.


Thorax ◽  
2017 ◽  
Vol 73 (6) ◽  
pp. 575-577 ◽  
Author(s):  
Alan Lunt ◽  
Lucy Mortimer ◽  
David Rees ◽  
Sue Height ◽  
Swee Lay Thein ◽  
...  

To detect and characterise different phenotypes of respiratory disease in children and young adults with sickle cell disease (SCD), 11 lung function and haematological biomarkers were analysed using k-means cluster analysis in a cohort of 114 subjects with SCD aged between 5 and 27 years. Three clusters were detected: cluster 1 had elevated pulmonary capillary blood volume, mixed obstructive/restrictive lung disease, hypoxia and moderately severe anaemia; cluster 2 were older patients with restrictive lung disease; and cluster 3 were younger patients with obstructive lung disease, elevated serum lactate dehydrogenase and bronchodilator reversibility. These results may inform more personalised management strategies to improve outcomes.


2018 ◽  
Vol 184 (2) ◽  
pp. 269-278 ◽  
Author(s):  
Julie Kanter ◽  
Miguel R. Abboud ◽  
Banu Kaya ◽  
Videlis Nduba ◽  
Carl Amilon ◽  
...  

Author(s):  
Mohamed Almuqamam ◽  
◽  
Swetha Madhavarapu ◽  
Nataly Apollonsky ◽  
◽  
...  

Sickle Cell Disease (SCD) is an inherited hemoglobinopathy, which results in production of abnormal hemoglobin S. HbSC disease is a variant of SCD, which shares a similar clinical complication profile to HbSS disease, but often thought to be a milder condition. In patients with SCD, Hb S in deoxygenated state undergoes polymerization, leading to hemolysis, vaso-occlusive events, and eventually end-organ damage. Among other complications in patients with SCD is increased risk of complications caused by parvovirus B19. We present a case of a 14-year-old female with HbSC disease who presented to the emergency room with complaint of abdominal pain and found to have splenic sequestration. Splenic sequestration progressed rapidly, Hemoglobin (hb) dropped to 4.6 g/dl and acute chest syndrome (ACS) developed. She was treated following the ACS protocol, received 4 units of Packed Red Blood Cells (PRBC) and subsequently underwent a single volume PRBC exchange transfusion. Considering her unusual presentation, with severe ARDS from alveolar hemorrhage requiring mechanical ventilation and multi-organ injury, several autoimmune and infectious conditions with a cytokine storm component including COVID-19 disease, were considered. Results of viral testing revealed parvovirus B19 IgM antibodies signifying an acute infection. She fully recovered with supportive care and was discharged home. Multisystem involvement simulating connective tissue disorders or malignancies with acute parvovirus B19 infection has been reported and is considered extremely rare. To our knowledge, there were no reports of pediatric patients with SC disease presenting with splenic sequestration and ACS in the setting of parvovirus B19 multisystem disease. Keywords: sickle cell disease; acute respiratory distress syndrome; acute chest syndrome; parvovirus B19.


Author(s):  
Dalal S. Aldossary ◽  
Vandy Black ◽  
Miriam O. Ezenwa ◽  
Agatha M. Gallo ◽  
Versie M. Johnson‐Mallard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document